Michelle J Di Fiore, MD
Rheumatology · Fremont
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 2
- 2 carriers
- Offices
- 4
Offices
4 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Plans that list them
2 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Fiore’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
2 of 2 plans
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A149040 · Current
Licensed to practise in California · since 2017 · expires 2027-05-31 · Rosalind Franklin University, the Chicago Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$125,283
Medicare paid this office $125,283 for 764 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 171 | $31,605 | $100 |
| Dxa bone density measurement of hip, pelvis, spine | 468 | $22,049 | $47 |
| Injection, denosumab, 1 mg | 12 | $21,964 | None |
| New patient visit (60+ min) | 81 | $14,361 | $177 |
| Long return visit (40+ min) | 56 | $12,645 | $158 |
See all 12 services
| Return visit (30+ min) | 171 | $31,605 | $100 |
| Dxa bone density measurement of hip, pelvis, spine | 468 | $22,049 | $47 |
| Injection, denosumab, 1 mg | 12 | $21,964 | None |
| New patient visit (60+ min) | 81 | $14,361 | $177 |
| Long return visit (40+ min) | 56 | $12,645 | $158 |
| Short return visit (20+ min) | 86 | $7,560 | $66 |
| New patient visit (45+ min) | 57 | $7,392 | $130 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 117 | $2,521 | $14 |
| Aspiration and/or injection of fluid from large joint | 14 | $1,267 | $60 |
| Dxa bone density measurement of forearm, finger, hand, or foot | 20 | $760 | $38 |
| Injection of drug or substance under skin or into muscle | 12 | $239 | $13 |
| Injection, methylprednisolone acetate, 1 mg | 16 | $80 | None |
Who their Medicare patients are
764 Original Medicare patients in 2024. Average age 73 · Under 65 5% · 85 and older 8% · Women 84% · Also on Medicaid 18% · Health risk score 0.95. At or below the middle of the specialty; the typical rheumatology clinician is at 1.38.
Conditions among them: High blood pressure 57% · Depression 18% · Diabetes 15% · Coronary heart disease 13% · Chronic kidney disease 13% · Cancer 13% · Atrial fibrillation 12% · COPD 10% · Heart failure 7% · Stroke 4% · Dementia 3%.
The office billed $475,703, Medicare allowed $162,151 and paid $125,283; for 3,294 services of 26 kinds; $22,266 of it was for drugs given in the office and $103,018 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 764 | 3,294 | 73 | 0.95 | $475,703 | $125,283 |
| 2023 | 684 | 1,657 | 73 | 0.89 | $419,804 | $103,819 |
| 2022 | 244 | 655 | 72 | 1.12 | $289,431 | $77,895 |
| 2021 | 59 | 130 | 71 | 0.90 | $55,064 | $15,289 |
| 2019 | 63 | 174 | 69 | 3.23 | $79,847 | $15,199 |
| 2018 | 44 | 138 | 68 | 3.28 | $66,448 | $13,002 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Return visit (30+ min) | 149 | $26,840 | $99 |
| Dxa bone density measurement of hip, pelvis, spine | 413 | $18,217 | $44 |
| New patient visit (60+ min) | 81 | $14,514 | $179 |
| New patient visit (45+ min) | 84 | $11,219 | $134 |
| Long return visit (40+ min) | 49 | $9,551 | $138 |
| Short return visit (20+ min) | 98 | $9,453 | $74 |
| Aspiration and/or injection of fluid from large joint | 18 | $1,545 | $67 |
| Dxa bone density measurement of forearm, finger, hand, or foot | 16 | $577 | $36 |
| Injection, methylprednisolone acetate, 40 mg | 23 | $255 | None |
2022: 8 services
| Return visit (30+ min) | 108 | $21,189 | $110 |
| New patient visit (60+ min) | 105 | $18,800 | $179 |
| Long return visit (40+ min) | 62 | $16,006 | $154 |
| New patient visit (45+ min) | 78 | $10,920 | $140 |
| Short return visit (20+ min) | 54 | $5,283 | $74 |
| Telephone medical discussion with physician, 21-30 minutes | 15 | $1,895 | $105 |
| Aspiration and/or injection of fluid from large joint | 15 | $1,271 | $67 |
| Injection, methylprednisolone acetate, 40 mg | 20 | $170 | None |
2021: 3 services
| New patient visit (60+ min) | 29 | $5,667 | $195 |
| New patient visit (45+ min) | 24 | $3,543 | $148 |
| Return visit (30+ min) | 15 | $1,847 | $115 |
2019: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $5,905 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,092 | $163 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,911 | $62 |
| Hospital discharge day management, 30 minutes or less | 26 | $1,626 | $63 |
| Hospital discharge day management, more than 30 minutes | 11 | $1,009 | $92 |
2018: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $6,652 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,759 | $172 |
| Hospital discharge day management, 30 minutes or less | 18 | $1,131 | $63 |
Medicaid work
$5,934 in 2024
Medicaid paid $5,934 for 54 billed services this clinician did in 2024, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 54 | $5,934 |
| 2024 | 54 | 1 | 14 | $5,934 |
| 2023 | 189 | 3 | 26 | $20,257 |
| 2022 | 12 | 1 | 12 | $1,295 |
| 2021 | 13 | 1 | 13 | $951 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 161 | $17,151 |
| New patient visit (45+ min) | 14 | $1,810 |
| Short return visit (20+ min) | 14 | $1,297 |
2022
| Return visit (30+ min) | 12 | $1,295 |
2021
| New patient visit (60+ min) | 13 | $951 |
Drugs they prescribed that Part D paid
$907,285
Pharmacies billed $907,285 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,202) in 2024. At or below the middle of the specialty; the typical rheumatology clinician is at 3%.
1,050 generic and fewer than 11 brand-name prescriptions · $907,285 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Enbrel Sureclick | 20 | $144,499 | $7,225 |
| Cimzia (2 Pack) | 17 | $139,867 | $8,227 |
| Humira(Cf) | 12 | $123,328 | $10,277 |
| Cosentyx | 11 | $77,472 | $7,043 |
| Teriparatide | 17 | $34,129 | $2,008 |
See all 21 drugs
| Enbrel Sureclick | 20 | $144,499 | $7,225 |
| Cimzia (2 Pack) | 17 | $139,867 | $8,227 |
| Humira(Cf) | 12 | $123,328 | $10,277 |
| Cosentyx | 11 | $77,472 | $7,043 |
| Teriparatide | 17 | $34,129 | $2,008 |
| Hydroxychloroquine Sulfate | 142 | $7,973 | $56 |
| Colchicine | 76 | $4,860 | $64 |
| Methotrexate | 131 | $4,111 | $31 |
| Cyclosporine | 13 | $3,721 | $286 |
| Leflunomide | 52 | $2,951 | $57 |
| Prednisone | 287 | $2,772 | $10 |
| Febuxostat | 12 | $2,767 | $231 |
| Celecoxib | 48 | $2,122 | $44 |
| Sulfasalazine | 15 | $661 | $44 |
| Diclofenac | 13 | $455 | $35 |
| Alendronate | 50 | $429 | $9 |
| Allopurinol | 35 | $400 | $11 |
| Gabapentin | 25 | $318 | $13 |
| Folic Acid | 35 | $285 | $8 |
| Meloxicam | 92 | $275 | $3 |
| Nabumetone | 16 | $162 | $10 |
Year by year
| 2024 | 1,202 | 228 | 0% (0) | None | $907,285 |
| 2023 | 1,051 | 199 | 0% (0) | 11% | $769,695 |
| 2022 | 661 | 134 | 0% (0) | None | $410,683 |
| 2021 | 170 | 46 | None | None | $140,410 |
| 2020 | 200 | 41 | None | 24% | $205,882 |
| 2019 | 168 | 62 | None | None | $49,802 |
| 2018 | 116 | 37 | None | 14% | $8,699 |
| 2017 | 16 | None | None | None | $1,047 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Enbrel Sureclick | 18 | $136,265 | $7,570 |
| Cimzia | 17 | $133,185 | $7,834 |
| Enbrel | 11 | $78,180 | $7,107 |
| Hydroxychloroquine Sulfate | 138 | $9,451 | $68 |
| Methotrexate | 99 | $6,266 | $63 |
| Colchicine | 48 | $4,013 | $84 |
| Leflunomide | 60 | $3,975 | $66 |
| Prednisone | 282 | $3,206 | $11 |
| Celecoxib | 24 | $1,121 | $47 |
| Allopurinol | 31 | $794 | $26 |
| Diclofenac | 26 | $706 | $27 |
| Alendronate | 35 | $632 | $18 |
| Sulfasalazine | 20 | $463 | $23 |
| Meloxicam | 69 | $388 | $6 |
| Omeprazole | 18 | $289 | $16 |
| Gabapentin | 20 | $236 | $12 |
| Folic Acid | 40 | $177 | $4 |
2022: 13 drugs
| Enbrel | 11 | $71,864 | $6,533 |
| Colchicine | 35 | $5,487 | $157 |
| Methotrexate | 91 | $4,756 | $52 |
| Leflunomide | 29 | $4,365 | $151 |
| Hydroxychloroquine Sulfate | 73 | $4,011 | $55 |
| Prednisone | 178 | $2,100 | $12 |
| Diclofenac | 12 | $831 | $69 |
| Celecoxib | 25 | $815 | $33 |
| Allopurinol | 22 | $204 | $9 |
| Meloxicam | 44 | $191 | $4 |
| Alendronate | 17 | $159 | $9 |
| Omeprazole | 12 | $153 | $13 |
| Folic Acid | 20 | $102 | $5 |
2021: 5 drugs
| Orencia | 11 | $45,231 | $4,112 |
| Colchicine | 17 | $2,998 | $176 |
| Methotrexate | 16 | $730 | $46 |
| Pregabalin | 21 | $617 | $29 |
| Prednisone | 24 | $425 | $18 |
2020: 6 drugs
| Humira | 11 | $63,235 | $5,749 |
| Hydroxychloroquine Sulfate | 16 | $2,713 | $170 |
| Pregabalin | 18 | $1,141 | $63 |
| Duloxetine | 24 | $644 | $27 |
| Diclofenac | 19 | $577 | $30 |
| Methotrexate | 16 | $537 | $34 |
2018: 1 drug
| Atorvastatin | 15 | $149 | $10 |
Money from drug and device companies
$16 in 2025
| 2025 | 1 | 1 | None | $16 |
| 2024 | 2 | 23 | None | $566 |
| 2023 | 1 | 1 | None | $118 |
| 2022 | 2 | 3 | None | $128 |
| 2021 | 1 | 1 | None | $28 |
| 2020 | 2 | 2 | None | $130 |
| 2019 | 2 | 2 | None | $216 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Gilead Sciences | None | $16 | 1 payment
|
See the published payment
| Gilead Sciences | Meals · 2025-05-11 | None | $16 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $566
| Abbvie | Rinvoq | $468 | 21 payments
|
| Aurinia Pharma U.S. | Lupkynis | $97 | 2 payments
|
2023: $118
| AstraZeneca Pharmaceuticals LP | Saphnelo | $118 | 1 payment
|
2022: $128
| Aurinia Pharma U.S. | Lupkynis | $93 | 1 payment
|
| Janssen Biotech | Tremfya | $35 | 2 payments
|
2021: $28
| GlaxoSmithKline | Benlysta | $28 | 1 payment
|
2020: $130
| Novartis Pharmaceuticals | Cosentyx | $104 | 1 payment
|
| GlaxoSmithKline | Benlysta | $26 | 1 payment
|
2019: $216
| GlaxoSmithKline | None | $122 | 1 payment
|
| Gilead Sciences | None | $94 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 96.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1790171072
- Licence
- CA A149040California A149040: Current · expires 2027-05-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RR0500X (207RR0500X); Internal medicine (207R00000X)
- Mailing address
- 3400 Data Dr, Rancho Cordova, CA, 95670
- NPI first listed
- 2015-04-13
- NPI last updated
- 2022-07-18
- NPI record certified
- 2022-07-18
This is when the NPI record was last certified, not a medical board exam.